An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Vertex Pharmaceuticals Incorporated
Study ID
NCT06832410
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Biological/Vaccine — BIOLOGICAL
    Infused into the hepatic portal vein.

Study Details

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Key Dates

Start date
Mar 31, 2025
Status verified
Mar 2026
Primary completion
Sep 17, 2026
Completion
Sep 17, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: VX-880

Primary Outcome Measure

Proportion of Participants who are Insulin Independent [ Time Frame: At 1 year After VX-880 infusion ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Perelman Center for Advanced Medicine - EndocrinologyPhiladelphiaPennsylvania19104-
Montefiore Clinical and Translational Research Center - EndocrinologyPittsburghPennsylvania15213-
UW University Hospital - EndocrinologyMadisonWisconsin53792-

Find similar trials in Philadelphia, PA

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Perelman Center for Advanced Medicine - Endocrinology· Philadelphia, PAMontefiore Clinical and Translational Research Center - Endocrinology· Pittsburgh, PAUW University Hospital - Endocrinology· Madison, WI

Related Studies